Rev-56 in Healthy Adults and NCFB Patients with P. aeruginosa

Phase 1, randomised, double-blind trial of Rev-56 in Non-cystic fibrosis bronchiectasis (NCFB) and Pseudomonas aeruginosa infection (7 cohorts), sponsored by Revagenix. Primary endpoints: Incidence and severity of treatment-emergent adverse events at 28 days and Number of participants with clinically significant abnormalities in lab parameters, vital signs, respiratory function, and ECG parameters at 28 days. Started Jul 2026; status: active, not recruiting.